BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10720692)

  • 1. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
    van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G
    J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells.
    Takahashi T; Chiba S; Nieda M; Azuma T; Ishihara S; Shibata Y; Juji T; Hirai H
    J Immunol; 2002 Apr; 168(7):3140-4. PubMed ID: 11907064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells.
    Takahashi T; Nieda M; Koezuka Y; Nicol A; Porcelli SA; Ishikawa Y; Tadokoro K; Hirai H; Juji T
    J Immunol; 2000 May; 164(9):4458-64. PubMed ID: 10779745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy.
    Takahashi T; Haraguchi K; Chiba S; Yasukawa M; Shibata Y; Hirai H
    Br J Haematol; 2003 Jul; 122(2):231-9. PubMed ID: 12846891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional characterization of long-term cultured rhesus macaque spleen-derived NKT cells.
    Gansuvd B; Hubbard WJ; Hutchings A; Thomas FT; Goodwin J; Wilson SB; Exley MA; Thomas JM
    J Immunol; 2003 Sep; 171(6):2904-11. PubMed ID: 12960313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
    Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T
    J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
    Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.
    van der Vliet HJ; Molling JW; von Blomberg BM; Kölgen W; Stam AG; de Gruijl TD; Mulder CJ; Janssen HL; Nishi N; van den Eertwegh AJ; Scheper RJ; van Nieuwkerk CJ
    Clin Immunol; 2005 Feb; 114(2):183-9. PubMed ID: 15639652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.
    Gadola SD; Dulphy N; Salio M; Cerundolo V
    J Immunol; 2002 Jun; 168(11):5514-20. PubMed ID: 12023346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells.
    Exley M; Garcia J; Balk SP; Porcelli S
    J Exp Med; 1997 Jul; 186(1):109-20. PubMed ID: 9207002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection.
    Motsinger A; Haas DW; Stanic AK; Van Kaer L; Joyce S; Unutmaz D
    J Exp Med; 2002 Apr; 195(7):869-79. PubMed ID: 11927631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.